中国科学家利用创新的细胞疗法治愈一名患者的糖尿病，在医学上取得了重大突破。这种开创性的治疗方法是由上海长征医院和分子细胞科学卓越中心的团队开发的。
患者是一名59岁的男性，患有2型糖尿病25年，面临着严重的并发症。尽管在2017年接受了肾移植，但他已经失去了对调节血糖水平至关重要的大部分胰岛功能，并依赖于每天多次注射胰岛素。
据《南华早报》报道，该患者于2021年7月接受了细胞移植。
值得注意的是，仅仅11周后，他就不再需要外部胰岛素了。在接下来的一年里，他逐渐减少，然后停止服用口服药物控制血糖。
首席研究员尹解释说：“随访检查显示，患者的胰岛功能得到了有效恢复。”。该患者已经33个月没有使用胰岛素了。
这一突破是糖尿病细胞治疗的重大进展。不列颠哥伦比亚大学教授Timothy Kieffer称赞了这项研究，称其为“糖尿病细胞治疗领域的重要进展”
中国团队的新疗法包括将患者的外周血单核细胞编程为“种子细胞”，在人工环境中重建胰岛组织。根据SCMP的报告，这种创新的方法利用了身体的再生能力，这是一个不断发展的领域，被称为再生医学。
Chinese scientists have made a major medical breakthrough by using innovative cell therapy to cure diabetes in a patient. This pioneering treatment was developed by teams from Shanghai Changzheng Hospital and the Centre for Excellence in Molecular Cell Science.
The patient, a 59-year-old man who had endured type 2 diabetes for 25 years, faced severe complications from the disease. Despite receiving a kidney transplant in 2017, he had lost most of his pancreatic islet function, which is crucial for regulating blood glucose levels, and was dependent on multiple daily insulin injections.
According to a South China Morning Post report, the patient received a cell transplant in July 2021.
Remarkably, just eleven weeks later, he no longer needed external insulin. Over the next year, he gradually reduced and then stopped taking oral medication for blood sugar control.
"Follow-up exams showed that the patient's pancreatic islet function was effectively restored," explained lead researcher Yin. The patient has now been insulin-free for 33 months.
This breakthrough is a significant advancement in cell therapy for diabetes. Timothy Kieffer, a professor at the University of British Columbia, praised the study, calling it "an important advance in the field of cell therapy for diabetes."
The Chinese team's new therapy involved programming the patient's peripheral blood mononuclear cells into "seed cells" to recreate pancreatic islet tissue in an artificial environment. This innovative approach leverages the body's regenerative capabilities, a growing